Greenwich LifeSciences expands the Phase III FLAMINGO-01 trial of GLSI-100 after a DSMB review, broadens enrollment, and advances plans toward a future BLA.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
Greenwich LifeSciences has announced key clinical and operational updates for FLAMINGO-01 (NCT05232916), its ongoing Phase III trial evaluating GLSI-100 (GP2 with GM-CSF) for the prevention of breast cancer recurrence in patients with HER2-positive breast cancer. The company confirmed that the independent Data Safety Monitoring Board (DSMB) reviewed the study in May 2026 and recommended that the trial continue without modification.
The company has also incorporated planned protocol amendments into the Phase III study following review by the U.S. Food and Drug Administration (FDA) and approvals from European regulatory authorities where applicable. Regulatory reviews of the amended protocol remain ongoing in the United Kingdom and Canada.
Revised Phase III Strategy Aims to Strengthen Clinical Evidence
The updated Phase III strategy is designed to improve the statistical robustness of FLAMINGO-01 while increasing operational flexibility. Key protocol modifications include expanding the study population, maintaining enrollment beyond interim analyses, increasing the number of recurrence events required for interim analyses, and incorporating a recently manufactured commercial-scale GP2 drug product lot into the trial.
The revised protocol also permits adaptive recommendations from an independent committee following interim analyses. These recommendations could include study resizing or modifications to subsequent analyses based on accumulating clinical evidence. According to the company, the changes are intended to strengthen the evidence supporting a potential future Biologics License Application (BLA) while preserving the scientific integrity of the study.
Expanded Eligibility Expected to Accelerate Enrollment
A major protocol amendment now allows patients of all human leukocyte antigen (HLA) types to participate in the randomized, blinded treatment arms of FLAMINGO-01, removing previous enrollment restrictions for non-HLA-A*02 patients, who account for approximately 55% of the target patient population.
Greenwich LifeSciences estimates that the amendment could increase enrollment by approximately 2.2-fold while proportionally increasing recurrence events available for interim analyses. The broader enrollment strategy is also expected to increase patient-years of follow-up, helping accelerate event accumulation while maintaining continuous recruitment throughout the study.
More than 1,500 patients have already been screened across approximately 180 clinical sites in 11 countries. The company plans to further expand recruitment into Norway, Denmark, Sweden, the United Kingdom, and Canada to support continued enrollment.
Preliminary Findings Support Continued Clinical Development
Preliminary observations from the fully enrolled 250-patient open-label non-HLA-A*02 cohort suggested an estimated 70% to 80% reduction in breast cancer recurrence following completion of the primary immunization series. These findings remain exploratory because they originate from an open-label cohort and have not yet been confirmed in the randomized Phase III study.
The preliminary observations are consistent with previously reported Phase IIb findings, which suggested approximately an 80% reduction in recurrence among treated patients with HER2-positive breast cancer.
The company also highlighted immune response and safety data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting, which support the continued clinical evaluation of GLSI-100.
Financial Position and Operational Progress
Greenwich LifeSciences reported an annual operating cash burn of approximately $10 million during 2025. The company expects to report a cash balance of approximately $8.9 million for the second quarter of 2026, with projected quarterly cash utilization of $2 million to $4 million.
The company has completed commercial-scale GP2 manufacturing and major clinical site start-up activities. Management indicated that future funding may be supported through licensing agreements, royalty financing, or other non-dilutive strategic partnerships.
Path Forward
Greenwich LifeSciences will continue implementing the revised Phase III protocol while regulatory reviews remain underway in the United Kingdom and Canada.
The trial includes planned interim analyses after 28 and 56 recurrence events, with the primary analysis scheduled after 133 events. Following interim analyses, an independent committee may recommend adaptive modifications, including study resizing or changes to subsequent analyses, as permitted under the revised protocol.
According to the company, positive interim analyses could support a future BLA submission, while patient enrollment may continue, if needed, up to a maximum of 2,000 participants depending on observed event rates.
Reference
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.